Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis

References

• Solberg IC, Lygren I, Jahnsen J, IBSEN Study Group, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population based inception cohort (IBSEN study). Scand J Gastroenterol. 2009;44(4):431–440.
   PubMed Web of Science ®Google Scholar
• Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384–413.
   PubMed Web of Science ®Google Scholar
• Fumery M, Singh S, Dulai PS, et al. Natural history of adult ulcerative colitis in population-based cohorts: a systematic review. Clin Gastroenterol Hepatol. 2018;16(3):343–356.
   PubMed Web of Science ®Google Scholar
• Harbord M, Eliakim R, Bettenworth D, European Crohn’s and Colitis Organisation [ECCO], et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11(7):769–784.
   PubMed Web of Science ®Google Scholar
• Ko CW, Singh S, Feuerstein JD, American Gastroenterological Association Institute Clinical Guidelines Committee, et al. AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis. Gastroenterology. 2019;156(3):748–764.
   PubMed Web of Science ®Google Scholar
• Murray A, Nguyen TM, Parker CE, et al. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2020;8(8):CD000543.
   PubMed Web of Science ®Google Scholar
• Murray A, Nguyen TM, Parker CE, et al. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2020;8(8):CD000544.
   PubMedGoogle Scholar
• Paridaens K, Fullarton JR, Travis SPL. Efficacy and safety of oral pentasa (prolonged-release mesalazine) in mild-to-moderate ulcerative colitis: a systematic review and meta-analysis. Curr Med Res Opin. 2021;37(11):1891–1900.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Hanauer SB, et al. The guide to guidelines in ulcerative colitis: interpretation and appropriate use in clinical practice. Gastroenterol Hepatol (NY). 2021;17(4 Suppl 4):3–13.
   PubMedGoogle Scholar
• Ungaro R, Colombel J-F, Lissoos T, et al. A treat-to-target update in ulcerative colitis: a systematic review. Am J Gastroenterol. 2019;114(6):874–883.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324–1338.
   PubMed Web of Science ®Google Scholar
• Colombel J-F, D'haens G, Lee W-J, et al. Outcomes and strategies to support a treat-to-target approach in inflammatory bowel disease: a systematic review. J Crohns Colitis. 2020;14(2):254–266.
   PubMed Web of Science ®Google Scholar
• Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583.
   PubMed Web of Science ®Google Scholar
• Solitano V, D’Amico F, Fiorino G, et al. Key strategies to optimize outcomes in mild-to-moderate ulcerative colitis. JCM. 2020;9(9):2905.
   Web of Science ®Google Scholar
• Nguyen NH, Fumery M, Dulai PS, et al. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. Lancet Gastroenterol Hepatol. 2018;3(11):742–753.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Gomollón F, Hinojosa J, et al. Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on ulcerative colitis: a real-life survey in Spain. J Crohns Colitis. 2010;4(5):567–574.
   PubMed Web of Science ®Google Scholar
• Carbonell-Estrany X, Dall’Agnola A, Fullarton JR, et al. Interaction between healthcare professionals and parents is a key determinant of parental distress during childhood hospitalisation for respiratory syncytial virus infection (European RSV Outcomes Study [EROS]). Acta Paediatr. 2018;107(5):854–860.
   PubMed Web of Science ®Google Scholar
• Wu C-Y, Yang H-Y, Luo S-F, et al. From rheumatoid factor to anti-citrullinated protein antibodies and anti-carbamylated protein antibodies for diagnosis and prognosis prediction in patients with rheumatoid arthritis. IJMS. 2021;22(2):686.
   Web of Science ®Google Scholar
• Campbell L, Pepper T, Shipman K. HbA1c: a review of non-glycaemic variables. J Clin Pathol. 2019;72(1):12–19.
   PubMed Web of Science ®Google Scholar
• Louis E. Fecal calprotectin: towards a standardized use for inflammatory bowel disease management in routine practice. J Crohns Colitis. 2015;9(1):1–3.
   PubMed Web of Science ®Google Scholar
• Honig G, Heller C, Hurtado-Lorenzo A. Defining the path forward for biomarkers to address unmet needs in inflammatory bowel diseases. Inflamm Bowel Dis. 2020;26(10):1451–1462.
   PubMed Web of Science ®Google Scholar
• Barberio B, Segal JP, Quraishi MN, et al. Efficacy of oral, topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and network meta-analysis. J Crohns Colitis. 2021;15(7):1184–1196.
   PubMed Web of Science ®Google Scholar
• Flourié B, Hagège H, Tucat G, MOTUS Study Investigators, et al. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Aliment Pharmacol Ther. 2013;37(8):767–775.
   PubMed Web of Science ®Google Scholar
• Dignass AU, Bokemeyer B, Adamek H, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7(7):762–769.
   PubMed Web of Science ®Google Scholar
• Rubin DT, Sninsky C, Siegmund E, et al. International perspectives on management of inflammatory bowel disease: opinion differences and similarities between patients and physicians from the IBD GAPPS survey. Inflam Bowel Dis. 2021;27(12):1942–1953.
   PubMed Web of Science ®Google Scholar
• Mitchell R, Kremer A, Westwood N, et al. Talking about life and IBD: a paradigm for improving patient-physician communication. J Crohns Colitis. 2009;3(1):1–3.
   PubMed Web of Science ®Google Scholar
• Irving P, Burisch J, Driscoll R, et al. IBD2020 global forum: results of an international patient survey on quality of care. Intest Res. 2018;16(4):537–545.
   PubMed Web of Science ®Google Scholar
• Danese S, Banerjee R, Cummings JRF, et al. Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i support therapy-access to rapid treatment (iSTART) approach. Intest Res. 2018;16(4):522–528.
   PubMed Web of Science ®Google Scholar
• Pedersen N, Thielsen P, Martinsen L, et al. EHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2014;20(12):2276–2285.
   PubMed Web of Science ®Google Scholar
• Moshkovska T, Stone MA, Smith RM, et al. Impact of a tailored patient preference intervention in adherence to 5-aminosalicylic acid medication in ulcerative colitis: results from an exploratory randomized controlled trial. Inflamm Bowel Dis. 2011;17(9):1874–1881.
   PubMed Web of Science ®Google Scholar
• Lees CW, Regueiro M, Mahadevan U. Innovation in inflammatory bowel disease care during the COVID-19 pandemic: results of a global telemedicine survey by the international organization for the study of inflammatory bowel disease. Gastroenterology. 2020;159(3):805–808.e1.
   PubMed Web of Science ®Google Scholar
• Martinez-Vinson C, Le S, Blachier A, et al. Effects of introduction of an inflammatory bowel disease nurse position on healthcare use. BMJ Open. 2020;10(5):e036929.
   PubMed Web of Science ®Google Scholar
• Furnham A. Response bias, social desirability and dissimulation. Pers Individ Dif. 1986;7(3):385–400.
   Web of Science ®Google Scholar